AP
BIOA

Antipodes Partners’s BioAge Labs BIOA Stock Holding History

Antipodes Partners’s Portfolio BIOA Stock Details BIOA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-915
Closed -$16K – 156
2026
Q1 		$16K Buy
+915
New +$17.6K ﹤0.01% 123

Other funds holding BIOA

ACM
AH Capital Management Menlo Park, California $14.2B AUM 20.01% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.95B AUM 773.9% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $1.93B AUM 134.74% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
OCA
Octagon Capital Advisors New York $1.11B AUM 866.76% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
MB
MPM BioImpact Boston, Massachusetts $1.64B AUM 245.64% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
PCH
Polar Capital Holdings London, United Kingdom $42.4B AUM 181.11% 1-Year Est. Return

Antipodes Partners's BIOA Position: Q2 2026 in Review

Antipodes Partners sold out of BioAge Labs (BIOA) in Q2 2026, closing a stake of 915 shares — an estimated $16K sold.

Antipodes Partners first reported a position in BIOA in Q1 2026 and held it in 1 quarter. The position peaked at $16K in Q1 2026. 151 funds tracked by Wall St. Rank hold BIOA as of Q2 2026.

  • Antipodes Partners reported no remaining BioAge Labs position as of Q2 2026 after selling out during the quarter.
  • Antipodes Partners sold 915 BioAge Labs shares in Q2 2026, an estimated $16K.
  • Antipodes Partners first reported a position in BioAge Labs in Q1 2026 and held it in 1 quarter.
  • Antipodes Partners's BioAge Labs position peaked at $16K in Q1 2026.
  • 151 funds tracked by Wall St. Rank held BioAge Labs as of Q2 2026.

Based on Antipodes Partners's 13F filing for Q2 2026, filed 6 Aug 2026.